Glycaemia and utilisation of technology across the lifespan of adults with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA)

Abstract Aims To evaluate the utilisation of technologies and associated glycaemia among adults with type 1 diabetes. Methods De-identified data from adults with type 1 diabetes (≥18 years old) in the Australian National Diabetes Audit (ANDA)–2019 were analysed. Proportions using insulin pumps or injections with continuous glucose monitoring (CGM) or capillary-glucose testing were compared. Technology use among adults was compared to young people ( Results 1,693 adults were analysed. Mean(±SD) age, diabetes duration, and HbA1c were 43.3±17.0 years, 20.3±14.3 years and 8.4%±1.7 [68±19mmol/mol], respectively. Among adults, 40% used at least one device, 27% used insulin pumps, and 23% used CGM. CGM was used by 62% of young people with subsidised access. Mean HbA1c was consistently lower among adults using CGM, insulin pumps, or combined insulin pump and CGM compared to standard care (8.3%±1.6 [67±18mmol/mol], 8.2%±1.4 [66±15mmol/mol], and 7.8%±1.4 [62±15mmol/mol] respectively compared to 8.6%±1.8 [70±20mmol/mol], p Conclusions Government subsidy is an important consideration for utilisation of technologies among adults with type 1 diabetes. Technology use across the adult lifespan was associated with lower HbA1c than insulin injections and capillary-glucose testing.